215 related articles for article (PubMed ID: 23664232)
1. Communicating risk of hereditary breast and ovarian cancer with an interactive decision support tool.
Rupert DJ; Squiers LB; Renaud JM; Whitehead NS; Osborn RJ; Furberg RD; Squire CM; Tzeng JP
Patient Educ Couns; 2013 Aug; 92(2):188-96. PubMed ID: 23664232
[TBL] [Abstract][Full Text] [Related]
2. Differences between women who pursued genetic testing for hereditary breast and ovarian cancer and their at-risk relatives who did not.
Katapodi MC; Northouse L; Pierce P; Milliron KJ; Liu G; Merajver SD
Oncol Nurs Forum; 2011 Sep; 38(5):572-81. PubMed ID: 21875844
[TBL] [Abstract][Full Text] [Related]
3. Hereditary breast/ovarian cancer syndrome: a primer for obstetricians/gynecologists.
Meaney-Delman D; Bellcross CA
Obstet Gynecol Clin North Am; 2013 Sep; 40(3):475-512. PubMed ID: 24021253
[TBL] [Abstract][Full Text] [Related]
4. Hereditary breast-ovarian cancer: clinical findings and medical management.
Marshall M; Solomon S
Plast Surg Nurs; 2007; 27(3):124-7. PubMed ID: 17901820
[TBL] [Abstract][Full Text] [Related]
5. Healthy women with a family history of breast cancer: impact of a tailored genetic counseling intervention on risk perception, knowledge, and menopausal therapy decision making.
Matloff ET; Moyer A; Shannon KM; Niendorf KB; Col NF
J Womens Health (Larchmt); 2006 Sep; 15(7):843-56. PubMed ID: 16999640
[TBL] [Abstract][Full Text] [Related]
6. Women's decisions regarding management of breast cancer risk.
MacDonald DJ
Medsurg Nurs; 2002 Aug; 11(4):183-6. PubMed ID: 12219430
[TBL] [Abstract][Full Text] [Related]
7. "Are you at risk for hereditary breast cancer?": development of a personal risk assessment tool for hereditary breast and ovarian cancer.
Cohn WF; Jones SM; Miesfeldt S
J Genet Couns; 2008 Feb; 17(1):64-78. PubMed ID: 18181014
[TBL] [Abstract][Full Text] [Related]
8. Genetic testing for breast and ovarian cancer susceptibility: evaluating direct-to-consumer marketing--Atlanta, Denver, Raleigh-Durham, and Seattle, 2003.
Centers for Disease Control and Prevention (CDC)
MMWR Morb Mortal Wkly Rep; 2004 Jul; 53(27):603-6. PubMed ID: 15254451
[TBL] [Abstract][Full Text] [Related]
9. Psychometric testing of the decisional conflict scale: genetic testing hereditary breast and ovarian cancer.
Katapodi MC; Munro ML; Pierce PF; Williams RA
Nurs Res; 2011; 60(6):368-77. PubMed ID: 22048556
[TBL] [Abstract][Full Text] [Related]
10. Women's interest in genetic testing for breast cancer risk: the influence of sociodemographics and knowledge.
Bottorff JL; Ratner PA; Balneaves LG; Richardson CG; McCullum M; Hack T; Chalmers K; Buxton J
Cancer Epidemiol Biomarkers Prev; 2002 Jan; 11(1):89-95. PubMed ID: 11815405
[TBL] [Abstract][Full Text] [Related]
11. Why Is Cancer Genetic Counseling Underutilized by Women Identified as at Risk for Hereditary Breast Cancer? Patient Perceptions of Barriers Following a Referral Letter.
Kne A; Zierhut H; Baldinger S; Swenson KK; Mink P; Veach PM; Tsai ML
J Genet Couns; 2017 Aug; 26(4):697-715. PubMed ID: 27826805
[TBL] [Abstract][Full Text] [Related]
12. Five families living with hereditary breast and ovarian cancer risk.
Norris J; Spelic SS; Snyder C; Tinley S
Clin J Oncol Nurs; 2009 Feb; 13(1):73-80. PubMed ID: 19193551
[TBL] [Abstract][Full Text] [Related]
13. Use of a Standardized Tool to Identify Women at Risk for Hereditary Breast and Ovarian.
Hessock M; Brewer T; Hutson S; Anderson J
Nurs Womens Health; 2021 Jun; 25(3):187-197. PubMed ID: 33933425
[TBL] [Abstract][Full Text] [Related]
14. Knowledge of risk management strategies, and information and risk management preferences of women at increased risk for ovarian cancer.
Tiller K; Meiser B; Gould L; Tucker K; Dudding T; Franklin J; Friedlander M; Andrews L
Psychooncology; 2005 Apr; 14(4):249-61. PubMed ID: 15386771
[TBL] [Abstract][Full Text] [Related]
15. Attitudes toward genetic testing for cancer risk after genetic counseling and decision support: a qualitative comparison between hereditary cancer types.
Wakefield CE; Kasparian NA; Meiser B; Homewood J; Kirk J; Tucker K
Genet Test; 2007; 11(4):401-11. PubMed ID: 18294057
[TBL] [Abstract][Full Text] [Related]
16. Intra-abdominal carcinomatosis after prophylactic oophorectomy in women of hereditary breast ovarian cancer syndrome kindreds associated with BRCA1 and BRCA2 mutations.
Casey MJ; Synder C; Bewtra C; Narod SA; Watson P; Lynch HT
Gynecol Oncol; 2005 May; 97(2):457-67. PubMed ID: 15863145
[TBL] [Abstract][Full Text] [Related]
17. Genetic counseling, testing, and screening for breast and ovarian cancer: practical and social considerations.
Khabele D; Runowicz CD
Curr Womens Health Rep; 2002 Jun; 2(3):163-9. PubMed ID: 12099190
[TBL] [Abstract][Full Text] [Related]
18. Participation in breast cancer susceptibility testing protocols: influence of recruitment source, altruism, and family involvement on women's decisions.
Geller G; Doksum T; Bernhardt BA; Metz SA
Cancer Epidemiol Biomarkers Prev; 1999 Apr; 8(4 Pt 2):377-83. PubMed ID: 10207643
[TBL] [Abstract][Full Text] [Related]
19. Hereditary breast and ovarian cancer (HBOC): clinical features and counseling for BRCA1 and BRCA2, Lynch syndrome, Cowden syndrome, and Li-Fraumeni syndrome.
Shulman LP
Obstet Gynecol Clin North Am; 2010 Mar; 37(1):109-33, Table of Contents. PubMed ID: 20494261
[TBL] [Abstract][Full Text] [Related]
20. Cancer surveillance behaviors in women presenting for clinical BRCA genetic susceptibility testing.
Loescher LJ; Lim KH; Leitner O; Ray J; D'Souza J; Armstrong CM
Oncol Nurs Forum; 2009 Mar; 36(2):E57-67. PubMed ID: 19273395
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
